25 Jul
2024
16:30 E.S.T.

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Read more

28 Jun
2024
11:04 E.S.T.

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Read more

20 Jun
2024
16:30 E.S.T.

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Read more

12 Jun
2024
10:27 E.S.T.

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Read more

04 Jun
2024
11:30 E.S.T.

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Read more

29 May
2024
16:30 E.S.T.

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

Read more

28 May
2024
16:30 E.S.T.

Cellectis Reports Financial Results for First Quarter 2024

Read more

24 May
2024
22:30 E.S.T.

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

Read more

06 May
2024
02:05 E.S.T.

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

Read more

02 May
2024
14:49 E.S.T.

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Read more